LLY vs PCRX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
PCRX exhibits a stable but mediocre Piotroski F-Score of 4/9, indicating a lack of strong fundamental momentum. The stock is severely overvalued relative to its deterministic baselines, trading at $23.86 despite a Graham Number of $7.79 and an Intrinsic Value of $1.12. While the balance sheet remains liquid with a current ratio of 4.54, the company is facing a crisis in profitability with earnings growth plummeting by 88.40% YoY. The massive discrepancy between the trailing P/E (149.12) and forward P/E (6.83) suggests the market is pricing in a recovery that is not yet supported by current growth metrics or insider activity.
Compare Another Pair
Related Comparisons
LLY vs PCRX: Head-to-Head Comparison
This page compares Eli Lilly and Company (LLY) and Pacira BioSciences, Inc. (PCRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.